...
首页> 外文期刊>Journal of Antimicrobial Chemotherapy >Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective)
【24h】

Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective)

机译:在败血症的最初几个小时中幸存下来:正确掌握基本知识(强化主义者的观点)

获取原文
获取原文并翻译 | 示例
           

摘要

Severe sepsis is a major cause of morbidity and mortality, claiming between 36 000 and 64 000 lives annually in the UK, with a mortality rate of 35%. International guidelines for the management of severe sepsis were published in 2004 by the Surviving Sepsis Campaign and condensed into two Care Bundles. In 2010, the Campaign published results from its improvement programme showing that, although an absolute mortality reduction of 5.4% was seen over a 2 year period in line with increasing compliance with the Bundles, reliability was not achieved and Bundle compliance reached only 31%. This article explores current challenges in sepsis care and opportunities for further improvements. Basic care tasks [microbiological sampling and antibiotic delivery within 1 h, fluid resuscitation, and risk stratification using serum lactate (or alternative)] are likely to benefit patients most, yet are unreliably performed. Barriers include lack of awareness and robust process, the lack of supporting controlled trials, and complex diagnostic criteria leading to recognition delays. Reliable, timely delivery of more complex life-saving tasks (such as early goal-directed therapy) demands greater awareness, faster recognition and initiation of basic care, and more effective collaboration between clinicians and nurses on the front line, in critical care and in specialist support services, such as microbiology and infectious diseases. Organizations such as Survive Sepsis, the Surviving Sepsis Campaign and the Global Sepsis Alliance are working to raise awareness and promote further improvement initiatives. Future developments will focus on sepsis biomarkers and microarray techniques to rapidly screen for pathogens, risk stratification using genetic profiling, and the development of novel therapeutic agents targeting immunomodulation.
机译:严重的败血症是发病率和死亡率的主要原因,在英国每年夺走36 000至64 000人的生命,死亡率为35%。幸存脓毒症运动于2004年发布了国际上有关严重脓毒症治疗的指导原则,并归纳为两个“护理包”。在2010年,Campaign公布了其改进计划的结果,该结果表明,尽管随着对Bundles遵从性的提高,两年内绝对死亡率降低了5.4%,但仍未达到可靠性,并且Bundle遵从性仅达到31%。本文探讨了败血症护理方面的当前挑战以及进一步改进的机会。基本护理任务[在1小时内进行微生物取样和抗生素输送,液体复苏以及使用血清乳酸盐(或替代品)进行风险分层]可能会使患者受益最多,但执行起来并不可靠。障碍包括缺乏认识和健全的流程,缺乏支持的对照试验以及导致识别延迟的复杂诊断标准。可靠,及时地执行更复杂的救生任务(例如早期的针对目标的治疗)需要更强的意识,更快地认识和启动基本护理,以及临床医生和护士在前线,重症监护和护理方面的更有效协作。专业支持服务,例如微生物学和传染病。存活脓毒症,存活脓毒症运动和全球脓毒症联盟等组织正在努力提高认识并促进进一步的改善措施。未来的发展将集中在败血症生物标志物和微阵列技术上,以快速筛查病原体,使用基因谱分析进行风险分层,以及开发针对免疫调节的新型治疗剂。

著录项

  • 来源
    《Journal of Antimicrobial Chemotherapy》 |2011年第2期|p.11-23|共13页
  • 作者

    Ron Daniels*;

  • 作者单位

    Critical Care and Anaesthesia, Good Hope Hospital, Heart of England NHS Foundation Trust, Birmingham B75 7RR, UK;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号